What happens if I stop taking either compound
Clear evidence-based candidates: People with obesity (BMI criteria plus comorbidities) People with type 2 diabetes Those with established high cardiovascular risk People with obstructive sleep apnea and obesity Those with metabolic-associated fatty liver disease Grey zone physician-guided, case by case: Prediabetes with strong family history Metabolic syndrome Significant compulsive eating patterns or food noise Alcohol use disorder very early evidence, not yet standard of care Not currently supported by evidence: Metabolically healthy individuals seeking optimisation or longevity Routine preventative use in low-risk populations That last category is where social media is running well ahead of the data
Platforms like MeAgain centralize timestamps for: Injections Symptoms Meals Hydration reminders Exportable trend reports It helps clinicians see whether palpitations cluster around: Low glucose Missed electrolytes Other triggers Decisions move from guesswork to targeted care
Structural insights into the dehydroascorbate reductase activity of human omega-class glutathione transferases
Patients who underwent a sleeve gastrectomy or gastric bypass lost about five times more weight after two years than people who had weekly injections of semaglutide or tirzepatide (the active ingredients in the anti-obesity drugs Wegovy and Zepbound, respectively), researchers reported Tuesday, June 17, at a meeting of the American Society for Metabolic and Bariatric Surgery
However, lyophilisation does not make the compound invincible
